Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo

Objective Hepatitis delta virus (HDV) was shown to persist for weeks in the absence of HBV and for months after liver transplantation, demonstrating the ability of HDV to persevere in quiescent hepatocytes. The aim of the study was to evaluate the impact of cell proliferation on HDV persistence in vitro and in vivo. Design Genetically labelled human sodium taurocholate cotransporting polypeptide (hNTCP)-transduced human hepatoma(HepG2) cells were infected with HBV/HDV and passaged every 7 days for 100 days in the presence of the entry inhibitor Myrcludex-B. In vivo, cell proliferation was triggered by transplanting primary human hepatocytes (PHHs) isolated from HBV/HDV-infected humanised mice into naïve recipients. Virological parameters were measured by quantitative real time polymerase chain reaction (qRT-PCR). Hepatitis delta antigen (HDAg), hepatitis B core antigen (HBcAg) and cell proliferation were determined by immunofluorescence. Results Despite 15 in vitro cell passages and block of viral spreading by Myrcludex-B, clonal cell expansion permitted amplification of HDV infection. In vivo, expansion of PHHs isolated from HBV/HDV-infected humanised mice was confirmed 3 days, 2, 4 and 8 weeks after transplantation. While HBV markers rapidly dropped in proliferating PHHs, HDAg-positive hepatocytes were observed among dividing cells at all time points. Notably, HDAg-positive cells appeared in clusters, indicating that HDV was transmitted to daughter cells during liver regeneration even in the absence of de novo infection. Conclusion This study demonstrates that HDV persists during liver regeneration by transmitting HDV RNA to dividing cells even in the absence of HBV coinfection. The strong persistence capacities of HDV may also explain why HDV clearance is difficult to achieve in HBV/HDV chronically infected patients.

[1]  A. Lohse,et al.  Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo , 2017, Gut.

[2]  M. Levrero,et al.  Aiming for cure in HBV and HDV infection. , 2016, Journal of hepatology.

[3]  Thorsten Lehr,et al.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. , 2016, Journal of hepatology.

[4]  Peng Jin,et al.  Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. , 2016, Cell stem cell.

[5]  A. Lohse,et al.  Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. , 2015, Journal of hepatology.

[6]  S. Davies,et al.  Chronic Hepatitis B Virus Infection: The Relation between Hepatitis B Antigen Expression, Telomere Length, Senescence, Inflammation and Fibrosis , 2015, PloS one.

[7]  A. Lohse,et al.  Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism , 2014, Hepatology.

[8]  M. Fälth,et al.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.

[9]  Sumedha Bagga,et al.  Cell Cycle Regulation During Viral Infection , 2014, Methods in molecular biology.

[10]  S. Polywka,et al.  Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. , 2014, Journal of hepatology.

[11]  S. Alavian,et al.  Hepatitis delta: the rediscovery. , 2013, Clinics in liver disease.

[12]  A. Lohse,et al.  The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. , 2013, Journal of hepatology.

[13]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[14]  R. Idilman,et al.  Entecavir treatment of chronic hepatitis D. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Ghabrial,et al.  Discovery of Novel dsRNA Viral Sequences by In Silico Cloning and Implications for Viral Diversity, Host Range and Evolution , 2012, PloS one.

[16]  Michael Thomaschewski,et al.  RGB marking with lentiviral vectors for multicolor clonal cell tracking , 2012, Nature Protocols.

[17]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[18]  M. Manns,et al.  Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. , 2012, Journal of hepatology.

[19]  I. Sporea,et al.  Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[20]  Stanley M. Lemon,et al.  Hepatitis C Virus Infection Causes Cell Cycle Arrest at the Level of Initiation of Mitosis , 2011, Journal of Virology.

[21]  Michael Thomaschewski,et al.  RGB marking facilitates multicolor clonal cell tracking , 2011, Nature Medicine.

[22]  D. Harnois Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta , 2011 .

[23]  A. Alibrandi,et al.  Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta Viruses , 2010, Journal of Virology.

[24]  M. Buti,et al.  Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. , 2010, Journal of hepatology.

[25]  S. Litwin,et al.  Detection of Clonally Expanded Hepatocytes in Chimpanzees with Chronic Hepatitis B Virus Infection , 2008, Journal of Virology.

[26]  [EASL clinical practice guidelines. Management of chronic hepatitis B]. , 2009, Gastroenterologie clinique et biologique.

[27]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[28]  E. Nicolas,et al.  Assembly of Hepatitis Delta Virus: Particle Characterization, Including the Ability To Infect Primary Human Hepatocytes , 2007, Journal of Virology.

[29]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon‐α2b , 2006 .

[30]  A. Andriulli,et al.  Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta , 2006, Hepatology.

[31]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[32]  H. Wu,et al.  Post-translational modification of delta antigen of hepatitis D virus. , 2006, Current topics in microbiology and immunology.

[33]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon-a 2 b , 2006 .

[34]  M. Manns,et al.  Lamivudine therapy in chronic delta hepatitis: a multicentre randomized‐controlled pilot study , 2005, Alimentary pharmacology & therapeutics.

[35]  M. Lai RNA Replication without RNA-Dependent RNA Polymerase: Surprises from Hepatitis Delta Virus , 2005, Journal of Virology.

[36]  Jinhong Chang,et al.  Development of a Novel System To Study Hepatitis Delta Virus Genome Replication , 2005, Journal of Virology.

[37]  S. Litwin,et al.  INAUGURAL ARTICLES: Hepatocyte turnover during resolution of a transient hepadnaviral infection , 2003 .

[38]  E. Christensen,et al.  Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B , 2000, Gut.

[39]  J. Taylor Replication of human hepatitis delta virus: influence of studies on subviral plant pathogens. , 1999, Advances in virus research.

[40]  R. Purcell,et al.  Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope , 1998, Hepatology.

[41]  D. Mathieu,et al.  Long‐term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis , 1995, Hepatology.

[42]  J. Taylor,et al.  Apparent helper-independent infection of woodchucks by hepatitis delta virus and subsequent rescue with woodchuck hepatitis virus , 1994, Journal of virology.

[43]  J. Taylor,et al.  Introduction of hepatitis delta virus into animal cell lines via cationic liposomes , 1994, Journal of virology.

[44]  P. Chen,et al.  Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles , 1991, Journal of virology.

[45]  Ding‐Shinn Chen,et al.  The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Michael Houghton,et al.  Structure, sequence and expression of the hepatitis delta (δ) viral genome , 1986, Nature.

[47]  M. Houghton,et al.  Structure, sequence and expression of the hepatitis delta (delta) viral genome. , 1986, Nature.

[48]  R. Purcell,et al.  delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .